Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans his Department has to publish bespoke clinical guidance for the treatment of people who are (a) immunocompromised or immunosuppressed and become infected with covid-19 reflecting recent innovations in the treatment of covid-19 and (b) ensure patients in this situation receive the same treatment opportunities across England.

Specific clinical guidance for the treatment of immunocompromised patients may be developed if research identifies effective treatments in the future. Immunocompromised patients are a priority cohort for research into therapeutic and prophylaxis treatments such as monoclonal antibody therapies, novel antivirals, and repurposed compounds.

The Department works closely with the National Health Service to ensure treatments are made available on an equitable basis.